Abstract 42P
Background
Cancer stem cells (CSC) motivate the investigation of novel anticancer-targeted therapies. In endometrial cancer (EC), overexpression of aldehyde dehydrogenase (ALDH) was associated with endometrial CSC, highlighting its therapeutic target potential. Photodynamic therapy (PDT), a minimally invasive anticancer approach, emerges as a promising targeted therapy for endometrial CSC, through a structural modulation of optimized photosensitisers with aldehyde moieties. Thus, the aim is to investigate PDT based on the 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-fused chlorins (PX), modulated to target endometrial CSC by incorporation of aldehyde substituents.
Methods
A solution of a mono-esther/mono-alcohol derivative chlorin was added to Dess-Martin periodinane in dichloromethane solution and stirred to synthesise a mono-aldehyde derivative of 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-fused chlorin (A-PX). The presence of the aldehyde group was confirmed by proton nuclear magnetic resonance (1H-NMR). The ALDH1A1-promoted oxidation of A-PX was followed through reverse-phase high-performance liquid chromatography (HPLC). This was done by reacting 50nM ALDH1A1 with 1mM A-PX in a 2% DMSO, Tris pH 7.5, KCl, DTT and β-NAD solution at 37 °C. The reaction was stopped every 30’ with acetonitrile. To evaluate A-PX-based PDT (7.5mW/cm2, 10J) the resazurin assay was performed on endometrial CSC.
Results
The A-PX 1H-NMR revealed a peak at 10.28ppm corresponding to the aldehyde. The kinetics of the enzymatic reaction, followed by HPLC, showed the decreasing relative area of the aldehyde peak (retention = 2’13’’) in parallel with the increase of the carboxylic acid (retention = 3’04’’) formed by ALDH1A1-promoted oxidation, reaching complete conversion at 120'. Preliminary results of the A-PX-PDT cytotoxicity on the endometrial CSC pointed to decreased proliferation, while A-PX per se did not show toxicity.
Conclusions
It was possible to develop chlorins able to interact with ALDH1A1, allowing the in situ modification of the hydrophilicity of the photosensitizer. A-PX seem to be effective PDT agents against endometrial CSC. The promising results encourage further studies to confirm this rationale for endometrial CSC-targeted PDT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Univ Coimbra.
Funding
Centre for Innovative Biomedicine and Biotechnology (CIBB) (UIDB/04539/2020, UIDP/04539/2020) and Coimbra Chemistry Centre (UIDB/00313/2020, UIDP/00313/2020) are supported by The Fundação para a Ciência e a Tecnologia (FCT), co-funded by COMPETE. Project Prova de Conceito (CENTRO-45-2021-30; 01/SAICT/2021, nº 180078) funded by Portugal2020. Beatriz Serambeque (2020.07672. BD ) and Bruna Costa (2022.12013. BD ) were awarded with a PhD Scholarship from FCT and European Social Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
14P - Peripheral immune kinetics in survival prediction of small cell lung cancer patients treated with immune checkpoint blockade therapy
Presenter: MIGUEL GALINDO CAMPOS
Session: Poster session 09
15P - CBL E3 ubiquitin ligases are key inhibitory regulators in PD-1/LAG-3 co-signaling in human cancers, targeted through bispecific co-blockade
Presenter: Luisa Chocarro
Session: Poster session 09
16P - Terminally exhausted CD8+ T cells and increased immunosuppressive soluble factors in malignant ascites of patients with gastric cancer with peritoneal metastasis
Presenter: Hye Sook Han
Session: Poster session 09
17P - Continued expansion of long-lived effect CD8+ T cells associates with durable response post-PD-1 blockade
Presenter: Robert Watson
Session: Poster session 09
18P - Exposure of calreticulin is required for vitamin C immunomediated cancer surveillance
Presenter: Alessandro Cavaliere
Session: Poster session 09
19P - Preclinical and clinical significance of VEGF deprivation in ovarian cancer through a specific active immunotherapy
Presenter: Yanelys Morera
Session: Poster session 09
20P - The essential role of DNA repair in the pharmacological activities of AST-3424
Presenter: Fanying Meng
Session: Poster session 09
21P - Implications of KMT2C knockdown for DNA damage repair in breast cancer
Presenter: Philip Bredin
Session: Poster session 09
22P - Clinical significance of DNA damage response mutations in early stage NSCLC
Presenter: Haoran Zhang
Session: Poster session 09
23P - PMC-309: A highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive
Presenter: Cheon Ho Park
Session: Poster session 09